ERBB2 and ovarian carcinoma: To determine whether miR-199a and miR-125b decrease angiogenesis potential by targeting HER2 and HER3, we established ovarian cancer stable cell lines overexpressing HER2 and HER3 using HER2 and HER3 cDNA plasmids without 3′ UTR regions, respectively.